BioLife Solutions Expands into $500 Million Cytokines Market Through Exclusive Qkine Partnership
核心洞察
BioLife Solutions (搜索) announced a multi-year agreement with Qkine Limited (搜索) on February 12, 2026, to distribute cytokine and growth factor products globally for cell and gene therapy manufacturing.
The partnership grants BioLife exclusive worldwide distribution rights to specific Qkine products for the CGT market, targeting the $500 million cytokines (搜索) market projected to reach $1 billion by 2030.
The companies plan to integrate select Qkine products into BioLife's proprietary CellSeal® Connect vial system through a collaborative process development and validation program.
BioLife Solutions (搜索), Inc. has entered into a strategic multi-year supply agreement with Qkine Limited (搜索) to distribute cytokine and growth factor products for cell and gene therapy manufacturing, marking the company's expansion into the rapidly growing cytokines (搜索) market valued at $500 million annually.
The agreement, announced on February 12, 2026, provides BioLife with exclusive worldwide distribution rights to specific Qkine products for the CGT market and non-exclusive rights to other Qkine products in the same sector. According to third-party market research, the global cytokines (搜索) market is projected to grow at a mid-teens compound annual rate, reaching $1 billion by 2030, driven by expanding CGT development pipelines.
Strategic Product Integration
The partnership extends beyond distribution, with both companies planning to collaborate on a process development and validation program. This initiative aims to enable Qkine to package certain products using BioLife's proprietary CellSeal® Connect vial system, which is designed for incorporation into closed system and automated CGT workflows.
"We are pleased to establish this strategic distribution and CellSeal® Connect product development relationship with Qkine, a recognized leader in the fast-growing cytokines (搜索) market," said Roderick de Greef, BioLife's Chairman and CEO. "Qkine's cytokine products are highly complementary to our cell culture supplement offerings and expand the portfolio of solutions we offer our CGT customers."
Market Positioning and Growth Strategy
The deal represents BioLife's targeted expansion into what the company identifies as attractive, fast-growing and profitable adjacent product categories. Cytokines (搜索) and growth factors (搜索) play a vital role in cell and gene therapy manufacturing by regulating and stimulating cell growth, activation and performance.
Dr. Robert Scoffin, Qkine's CEO, emphasized the collaborative potential: "This collaboration brings together our expertise in cytokine innovation with BioLife's extensive reach and customer relationships in the CGT market. Together, we aim to deliver greater value to customers and help advance the development and manufacture of next-generation cell and gene therapies."
Operational Synergies
The Qkine partnership aligns with BioLife's recent infrastructure investments, including the opening of the Aby J. Mathew Center for Biopreservation Excellence in November 2025. Both initiatives are designed to deepen BioLife's role in cell and gene therapy process optimization and may reinforce cross-selling opportunities around CellSeal Connect (搜索) and other integrated tools.
The agreement specifically targets cytokines (搜索) along with other biologically active cell culture media components as part of BioLife's long-term growth strategy, positioning the company to capture a larger share of the expanding CGT manufacturing ecosystem as therapies progress through clinical development and into commercial use.